Collaborators GBDCD. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of Disease Study 2021. Lancet. 2024;403(10440):2100–32. https://doi.org/10.1016/S0140-6736(24)00367-2.

Article  Google Scholar 

Writing C, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC Expert Consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the management of atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366–418. https://doi.org/10.1016/j.jacc.2022.07.006.

Article  Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary Prevention of Cardiovascular Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2019;140(11):e563–95. https://doi.org/10.1161/CIR.0000000000000677.

Article  PubMed  PubMed Central  Google Scholar 

Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–806. https://doi.org/10.1093/eurheartj/ehab551.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordestgaard BG. Triglyceride-Rich lipoproteins and Atherosclerotic Cardiovascular Disease: New insights from Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547–63. https://doi.org/10.1161/CIRCRESAHA.115.306249.

Article  CAS  PubMed  Google Scholar 

Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42(42):4324–32. https://doi.org/10.1093/eurheartj/ehab432.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse Cardiovascular events in patients at High Cardiovascular Risk: the STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268–80. https://doi.org/10.1001/jama.2020.22258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531–42. https://doi.org/10.1056/NEJMoa1715944.

Article  CAS  PubMed  Google Scholar 

Malick WA, Do R, Rosenson RS. Severe hypertriglyceridemia: existing and emerging therapies. Pharmacol Ther. 2023;251:108544. https://doi.org/10.1016/j.pharmthera.2023.108544.

Article  CAS  PubMed  Google Scholar 

Shaik A, Rosenson RS. Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk reduction. Cardiovasc Drugs Ther. 2021;35(3):677–90. https://doi.org/10.1007/s10557-021-07168-0.

Article  CAS  PubMed  Google Scholar 

Rosenson RS, Shaik A, Song W. New therapies for lowering triglyceride-rich lipoproteins: JACC Focus Seminar 3/4. J Am Coll Cardiol. 2021;78(18):1817–30. https://doi.org/10.1016/j.jacc.2021.08.051.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol. 2022;19(3):168–79. https://doi.org/10.1038/s41569-021-00613-5.

Article  CAS  PubMed  Google Scholar 

Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114(10):611–24. https://doi.org/10.1042/CS20070308.

Article  CAS  PubMed  Google Scholar 

Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19(3):472–84. https://doi.org/10.1161/01.atv.19.3.472.

Article  CAS  PubMed  Google Scholar 

Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem. 1995;270(22):13470–5. https://doi.org/10.1074/jbc.270.22.13470.

Article  CAS  PubMed  Google Scholar 

Giammanco A, Spina R, Cefalu AB, Averna M. APOC-III: a gatekeeper in Controlling triglyceride metabolism. Curr Atheroscler Rep. 2023;25(3):67–76. https://doi.org/10.1007/s11883-023-01080-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46(2):375–82. https://doi.org/10.1016/s0006-291x(72)80149-9.

Article  CAS  PubMed  Google Scholar 

Kinnunen PK, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 1976;65(3):354–7. https://doi.org/10.1016/0014-5793(76)80145-7.

Article  CAS  PubMed  Google Scholar 

Ginsberg HN, Goldberg IJ. Broadening the scope of Dyslipidemia Therapy by Targeting APOC3 (apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like protein 3). Arterioscler Thromb Vasc Biol. 2023;43(3):388–98. https://doi.org/10.1161/ATVBAHA.122.317966.

Article  CAS  PubMed  Google Scholar 

Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90(5):1889–900. https://doi.org/10.1172/JCI116066.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161–72. https://doi.org/10.1016/j.cell.2015.01.036.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, et al. LDL particle number and risk of Future Cardiovascular Disease in the Framingham offspring study - implications for LDL management. J Clin Lipidol. 2007;1(6):583–92. https://doi.org/10.1016/j.jacl.2007.10.001.

Article  PubMed  PubMed Central  Google Scholar 

Grundy SM, Small LDL. Atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95(1):1–4. https://doi.org/10.1161/01.cir.95.1.1.

Article  CAS  PubMed  Google Scholar 

Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and Cardiovascular Risk in women and men. J Am Coll Cardiol. 2024;83(23):2262–73. https://doi.org/10.1016/j.jacc.2024.03.423.

Article  CAS  PubMed  Google Scholar 

Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and Non-high-density Lipoprotein Cholesterol as a marker of Cardiovascular Risk. J Am Heart Assoc. 2022;11(20):e025858. https://doi.org/10.1161/JAHA.122.025858.

Article  PubMed  PubMed Central  Google Scholar